Info

Genitrix, LLC, a privately held biotechnology company headquartered in Cambridge, MA, is developing innovative therapeutic vaccines based on its powerful OpsonokineTM technology. OpsonokinesTM are "sticky" cytokines that attach to cells automatically, on contact, making it possible to put the right cytokine in the right place in the right amount, and keep it there. The Company's lead OpsonokineTM molecule overcomes the "immunogenicity barrier", historically a major obstacle to immunotherapy, by targeting the body's critical "antigen presenting cells" and stimulating a potent "killer" T cell response. Genitrix is currently developing products, based on this lead molecule, for the treatment of cancer and chronic viral infections.